Similarly, in AD models, the anti-inflammatory cytokine interferon-gamma acts as a potential therapeutic target of AD (122), and C/EBPβ knockdown has been associated with reduced amyloid-beta (Aβ) pathology and improved cognitive outcomes (47). This evidence concerns the gene IFNG and Alzheimer disease.